NASDAQ:RLAY

Relay Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy RLAY

*Your capital is at risk

$18.83

-0.620 (-3.19%)

At Close: Jul 31, 2026

Relay Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -48.20. In total, the insiders bought 6.59M and sold 911.42K RLAY shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-48.20
● Buy	6.59M shares
● Sell	911.42K shares
49% Buy Activity Weak Positive Correlation
Sell Signal Medium Confidence Jun 22, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -48.2. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 28, 2026 Sell	Common Stock S-Sale	Bergstrom Donald A President, R&d	CEO / President	2 237 Value: $41.6K
Jul 28, 2026 Sell	Common Stock S-Sale	Rahmer Peter See Remarks	Officer	748 Value: $13.9K
Jul 28, 2026 Sell	Common Stock S-Sale	Catinazzo Thomas Chief Financial Officer	C-Suite Officer	1 459 Value: $27.2K
Jul 07, 2026 Sell	Common Stock S-Sale	Patel Sanjiv President And CEO	CEO / President	48 199 Value: $943.7K
Jul 06, 2026 Sell	Common Stock S-Sale	Catinazzo Thomas Chief Financial Officer	C-Suite Officer	17 717 Value: $331.1K
Jul 06, 2026 Sell	Common Stock S-Sale	Bergstrom Donald A President, R&d	CEO / President	8 660 Value: $162.0K
Jun 30, 2026 Buy	Common Stock A-Award	Patel Sanjiv President And CEO	CEO / President	3 056 Value: $21.2K
Jun 30, 2026 Sell	Common Stock S-Sale	Rahmer Peter See Remarks	Officer	50 000 Value: $954.5K
Jun 30, 2026 Buy	Common Stock A-Award	Rahmer Peter See Remarks	Officer	3 056 Value: $21.2K
Jun 22, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Bergstrom Donald A President, R&d	CEO / President	93 456 Value: $385.0K
Jun 22, 2026 Buy	Common Stock M-Exempt	Catinazzo Thomas Chief Financial Officer	C-Suite Officer	61 563 Value: $321.4K
Jun 22, 2026 Buy	Common Stock M-Exempt	Catinazzo Thomas Chief Financial Officer	C-Suite Officer	56 323 Value: $283.9K
Jun 22, 2026 Buy	Common Stock M-Exempt	Catinazzo Thomas Chief Financial Officer	C-Suite Officer	51 560 Value: $229.4K
Jun 22, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Catinazzo Thomas Chief Financial Officer	C-Suite Officer	51 560 Value: $229.4K
Jun 22, 2026 Sell	Common Stock S-Sale	Catinazzo Thomas Chief Financial Officer	C-Suite Officer	51 560 Value: $875.0K
Jun 22, 2026 Sell	Common Stock S-Sale	Catinazzo Thomas Chief Financial Officer	C-Suite Officer	17 717 Value: $301.4K
Jun 22, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Catinazzo Thomas Chief Financial Officer	C-Suite Officer	56 323 Value: $283.9K
Jun 22, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Catinazzo Thomas Chief Financial Officer	C-Suite Officer	61 563 Value: $321.4K
Jun 22, 2026 Sell	Common Stock S-Sale	Bergstrom Donald A President, R&d	CEO / President	93 456 Value: $1.58M
Jun 22, 2026 Buy	Common Stock M-Exempt	Bergstrom Donald A President, R&d	CEO / President	93 456 Value: $385.0K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Coats Lonnel Director	Director	32 947 Value: $464.2K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Mazumdar Claire Director	Director	32 947 Value: $464.2K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Dable Habib J Director	Director	32 947 Value: $464.2K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Hill Linda A Director	Director	32 947 Value: $464.2K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Borisy Alexis Director	Director	32 947 Value: $464.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RELAY THERAPEUTICS INC.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for pa...

Read Full Profile Here